We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Crism Therapeutics Corporation | LSE:CRTX | London | Ordinary Share | VGG042401262 | ORD NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.25 | 5.00 | 5.50 | 5.375 | 5.25 | 5.25 | 42,434 | 15:07:01 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Mineral Royalty Traders | 512k | -9.65M | -0.0069 | -7.61 | 73.13M |
From Jun 2019 to Jun 2024
The U.S. Food and Drug Administration said Friday it was updating the label of Merck & Co.'s (MRK) Singulair and similar asthma medications to discuss reports of neuropsychiatric events such as agitation, depression, insomnia and suicidal thinking.
The new labeling also applies to Accolate by AstraZeneca PLC (AZN) and Zyflo, by Cornerstone Therapeutics Inc. (CRTX).
The FDA said in a posting to its Web site that "patients and healthcare professionals should be aware of the potential for neuropsychiatric events with these medications."
Singulair, one of Merck's top-selling products, is approved to treat asthma and allergies while Accolate and Zyflo are approved to treat asthma.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com
1 Year Crism Therapeutics Chart |
1 Month Crism Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
